It was 'imminent' five weeks ago according to Paul Rennie. One wonders what difficulties PAR has created for the FDA.
- Forums
- ASX - By Stock
- PAR
- FDA delay for ph 3 trial approval
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
2.27%
!
43.0¢

FDA delay for ph 3 trial approval, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
43.0¢ |
Change
-0.010(2.27%) |
Mkt cap ! $168.9M |
Open | High | Low | Value | Volume |
44.5¢ | 44.5¢ | 42.5¢ | $112.7K | 261.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 93157 | 42.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.0¢ | 14144 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 106823 | 0.425 |
4 | 35427 | 0.420 |
7 | 62805 | 0.415 |
10 | 134244 | 0.410 |
5 | 23300 | 0.405 |
Price($) | Vol. | No. |
---|---|---|
0.430 | 33449 | 9 |
0.435 | 18252 | 6 |
0.440 | 32910 | 5 |
0.445 | 11617 | 5 |
0.450 | 34500 | 1 |
Last trade - 11.25am 16/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online